Cargando…
Gene Therapy for Malignant and Benign Gynaecological Disorders: A Systematic Review of an Emerging Success Story
SIMPLE SUMMARY: This review discusses all the major advances in gene therapy of gynaecological disorders, highlighting the novel and potentially therapeutic perspectives associated with such an approach. It specifically focuses on the gene therapy strategies against major gynaecological malignant di...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265289/ https://www.ncbi.nlm.nih.gov/pubmed/35805007 http://dx.doi.org/10.3390/cancers14133238 |
_version_ | 1784743176465022976 |
---|---|
author | Drakopoulou, Ekati Anagnou, Nicholas P. Pappa, Kalliopi I. |
author_facet | Drakopoulou, Ekati Anagnou, Nicholas P. Pappa, Kalliopi I. |
author_sort | Drakopoulou, Ekati |
collection | PubMed |
description | SIMPLE SUMMARY: This review discusses all the major advances in gene therapy of gynaecological disorders, highlighting the novel and potentially therapeutic perspectives associated with such an approach. It specifically focuses on the gene therapy strategies against major gynaecological malignant disorders, such as ovarian, cervical, and endometrial cancer, as well as benign disorders, such as uterine leiomyomas, endometriosis, placental, and embryo implantation disorders. The above therapeutic strategies, which employ both viral and non-viral systems for mutation compensation, suicide gene therapy, oncolytic virotherapy, antiangiogenesis and immunopotentiation approaches, have yielded promising results over the last decade, setting the grounds for successful clinical trials. ABSTRACT: Despite the major advances in screening and therapeutic approaches, gynaecological malignancies still present as a leading cause of death among women of reproductive age. Cervical cancer, although largely preventable through vaccination and regular screening, remains the fourth most common and most lethal cancer type in women, while the available treatment schemes still pose a fertility threat. Ovarian cancer is associated with high morbidity rates, primarily due to lack of symptoms and high relapse rates following treatment, whereas endometrial cancer, although usually curable by surgery, it still represents a therapeutic problem. On the other hand, benign abnormalities, such as fibroids, endometriosis, placental, and embryo implantation disorders, although not life-threatening, significantly affect women’s life and fertility and have high socio-economic impacts. In the last decade, targeted gene therapy approaches toward both malignant and benign gynaecological abnormalities have led to promising results, setting the ground for successful clinical trials. The above therapeutic strategies employ both viral and non-viral systems for mutation compensation, suicide gene therapy, oncolytic virotherapy, antiangiogenesis and immunopotentiation. This review discusses all the major advances in gene therapy of gynaecological disorders and highlights the novel and potentially therapeutic perspectives associated with such an approach. |
format | Online Article Text |
id | pubmed-9265289 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92652892022-07-09 Gene Therapy for Malignant and Benign Gynaecological Disorders: A Systematic Review of an Emerging Success Story Drakopoulou, Ekati Anagnou, Nicholas P. Pappa, Kalliopi I. Cancers (Basel) Review SIMPLE SUMMARY: This review discusses all the major advances in gene therapy of gynaecological disorders, highlighting the novel and potentially therapeutic perspectives associated with such an approach. It specifically focuses on the gene therapy strategies against major gynaecological malignant disorders, such as ovarian, cervical, and endometrial cancer, as well as benign disorders, such as uterine leiomyomas, endometriosis, placental, and embryo implantation disorders. The above therapeutic strategies, which employ both viral and non-viral systems for mutation compensation, suicide gene therapy, oncolytic virotherapy, antiangiogenesis and immunopotentiation approaches, have yielded promising results over the last decade, setting the grounds for successful clinical trials. ABSTRACT: Despite the major advances in screening and therapeutic approaches, gynaecological malignancies still present as a leading cause of death among women of reproductive age. Cervical cancer, although largely preventable through vaccination and regular screening, remains the fourth most common and most lethal cancer type in women, while the available treatment schemes still pose a fertility threat. Ovarian cancer is associated with high morbidity rates, primarily due to lack of symptoms and high relapse rates following treatment, whereas endometrial cancer, although usually curable by surgery, it still represents a therapeutic problem. On the other hand, benign abnormalities, such as fibroids, endometriosis, placental, and embryo implantation disorders, although not life-threatening, significantly affect women’s life and fertility and have high socio-economic impacts. In the last decade, targeted gene therapy approaches toward both malignant and benign gynaecological abnormalities have led to promising results, setting the ground for successful clinical trials. The above therapeutic strategies employ both viral and non-viral systems for mutation compensation, suicide gene therapy, oncolytic virotherapy, antiangiogenesis and immunopotentiation. This review discusses all the major advances in gene therapy of gynaecological disorders and highlights the novel and potentially therapeutic perspectives associated with such an approach. MDPI 2022-06-30 /pmc/articles/PMC9265289/ /pubmed/35805007 http://dx.doi.org/10.3390/cancers14133238 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Drakopoulou, Ekati Anagnou, Nicholas P. Pappa, Kalliopi I. Gene Therapy for Malignant and Benign Gynaecological Disorders: A Systematic Review of an Emerging Success Story |
title | Gene Therapy for Malignant and Benign Gynaecological Disorders: A Systematic Review of an Emerging Success Story |
title_full | Gene Therapy for Malignant and Benign Gynaecological Disorders: A Systematic Review of an Emerging Success Story |
title_fullStr | Gene Therapy for Malignant and Benign Gynaecological Disorders: A Systematic Review of an Emerging Success Story |
title_full_unstemmed | Gene Therapy for Malignant and Benign Gynaecological Disorders: A Systematic Review of an Emerging Success Story |
title_short | Gene Therapy for Malignant and Benign Gynaecological Disorders: A Systematic Review of an Emerging Success Story |
title_sort | gene therapy for malignant and benign gynaecological disorders: a systematic review of an emerging success story |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265289/ https://www.ncbi.nlm.nih.gov/pubmed/35805007 http://dx.doi.org/10.3390/cancers14133238 |
work_keys_str_mv | AT drakopoulouekati genetherapyformalignantandbenigngynaecologicaldisordersasystematicreviewofanemergingsuccessstory AT anagnounicholasp genetherapyformalignantandbenigngynaecologicaldisordersasystematicreviewofanemergingsuccessstory AT pappakalliopii genetherapyformalignantandbenigngynaecologicaldisordersasystematicreviewofanemergingsuccessstory |